Cediranib
Recurrent Osteosarcoma
National Cancer Institute (NCI)Small moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Recurrent Osteosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
Ipilimumab Children's National Research Institute | Phase 2 | BB |
Irinotecan National Cancer Institute (NCI) | Phase 2 | BB |
Olaparib Fundación de investigación HM | Phase 2 | BB |
Cixutumumab National Cancer Institute (NCI) | Phase 2 | B |
View all 30 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →